NYSE:NVSNovartis Stock Price, Forecast & News

$87.43

+1.15 (+1.33 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$85.82

Now: $87.43▼

$87.59

50-Day Range

$83.41

MA: $85.89▼

$89.78

52-Week Range

$69.18

Now: $87.43▼

$99.84

Volume2.56 million shs

Average Volume1.64 million shs

Market Capitalization$200.37 billion

P/E Ratio16.69

Dividend Yield2.30%

Beta0.51

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Beat the Market (BTM) Rank^™

3.1 Analyst's Opinion

Consensus Rating
Novartis has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $107.00, Novartis has a potential upside of 22.4% from its current price of $87.43.
Amount of Analyst Coverage
Novartis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.3 Community Rank

Outperform Votes
Novartis has received 495 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novartis has received 567 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novartis has received 53.39% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote “Outperform” if you believe NVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Novartis is a leading dividend payer. It pays a dividend yield of 2.30%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Novartis has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Novartis is 38.36 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novartis will have a dividend payout ratio of 32.01 % next year. This indicates that Novartis will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novartis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.01% of the stock of Novartis is held by insiders.
Percentage Held by Institutions
Only 10.78% of the stock of Novartis is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Novartis are expected to grow by 11.35% in the coming year, from $5.64 to $6.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novartis is 16.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.30.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novartis is 16.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.64.
Price to Earnings Growth Ratio
Novartis has a PEG Ratio of 1.93. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novartis has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.99 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:NVS

Previous Symbol

CUSIPN/A

CIK1114448

Webwww.novartis.com

Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.50

Current Ratio0.74

Quick Ratio0.53

Price-To-Earnings

Trailing P/E Ratio16.69

Forward P/E Ratio15.50

P/E Growth1.93

Sales & Book Value

Annual Sales$47.50 billion

Price / Sales4.22

Cash Flow$7.81 per share

Price / Cash Flow11.20

Book Value$22.24 per share

Price / Book3.93

Profitability

EPS (Most Recent Fiscal Year)$5.24

Net Income$11.73 billion

Net Margins24.97%

Return on Equity24.39%

Return on Assets10.84%

Miscellaneous

Employees103,914

Outstanding Shares2,291,800,000

Market Cap$200.37 billion

Next Earnings Date7/16/2020 (Estimated)

OptionableOptionable

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock been impacted by COVID-19 (Coronavirus)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVS shares have increased by 6.4% and is now trading at $87.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novartis?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novartis.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Novartis.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, April, 28th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.19. The firm earned $12.28 billion during the quarter, compared to analysts' expectations of $11.92 billion. Novartis had a return on equity of 24.39% and a net margin of 24.97%. Novartis's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.21 earnings per share. View Novartis' earnings history.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Monday, February 3rd. Investors of record on Wednesday, March 4th will be paid a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86. View Novartis' dividend history.

What price target have analysts set for NVS?

11 brokerages have issued 1 year price objectives for Novartis' shares. Their forecasts range from $100.00 to $116.00. On average, they anticipate Novartis' share price to reach $107.00 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View analysts' price targets for Novartis.

Has Novartis been receiving favorable news coverage?

News stories about NVS stock have been trending negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novartis earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutNovartis.

Are investors shorting Novartis?

Novartis saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,820,000 shares, a decrease of 8.1% from the April 30th total of 3,070,000 shares. Based on an average trading volume of 2,830,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.1% of the company's shares are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Gilead Sciences (GILD), NVIDIA (NVDA) and Merck & Co., Inc. (MRK).

Who are Novartis' key executives?

Novartis' management team includes the following people:

Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
Mr. Harry Kirsch, Chief Financial Officer (Age 54)
Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (1.05%), Loomis Sayles & Co. L P (0.45%), Franklin Resources Inc. (0.39%), Fisher Asset Management LLC (0.37%), Mawer Investment Management Ltd. (0.34%) and Wells Fargo & Company MN (0.29%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Jennison Associates LLC, Primecap Management Co. CA, Janus Henderson Group PLC, Capital Research Global Investors, Voloridge Investment Management LLC, and Schafer Cullen Capital Management Inc.

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Mawer Investment Management Ltd., Fred Alger Management LLC, Morgan Stanley, Capital International Investors, Two Sigma Investments LP, Wellington Management Group LLP, Bartlett & Co. LLC, and Advisor Group Holdings Inc..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $87.43.

How big of a company is Novartis?

Novartis has a market capitalization of $200.37 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff